摘要:
Disclosed are methods for inhibiting TNFα expression, IL-1β expression, iNOS expression, and NF-κB activity and methods for treating autoimmune disease, cancer, or atherosclerosis with a compound of the following formula:
摘要:
A compound of the following formula: wherein X, Y, and Z are as defined herein. Also disclosed are methods for inhibiting TNFα expression, IL-1β expression, iNOS expression, and NF-κB activity and methods for treating autoimmune disease, cancer, or atherosclerosis with such a compound.
摘要:
A compound of the following formula: wherein X, Y, and Z are as defined herein. Also disclosed are methods for inhibiting TNFα expression, IL-1β expression, iNOS expression, and NF-κB activity and methods for treating autoimmune disease, cancer, or atherosclerosis with such a compound.
摘要:
Disclosed are methods for inhibiting TNFα expression, IL-1β expression, iNOS expression, and NF-κB activity and methods for treating autoimmune disease, cancer, or atherosclerosis with a compound of the following formula:
摘要:
A compound of the following formula: wherein R1, R2, R3, R4, R5, T, U, V, X, Y, Z, G, and Z are defined herein. It also discloses a method of treating an angiogenesis-related disorder, e.g., cancer or age-related macular degeneration, with such a compound.
摘要:
A compound of the following formula: wherein R1, R2, R3, R4, R5,T, U, V, X, Y, Z, G, and Z are defined herein. It also discloses a method of treating an angiogenesis-related disorder, e.g., cancer or age-related macular degeneration, with such a compound.
摘要:
Compound of Formula A and pharmaceutically acceptable salts thereof and crystalline Forms I and II of Compound of Formula A! Also, methods for the preparation of such compounds, pharmaceutical compositions comprising such compounds, and methods for their uses.
摘要:
Compound of Formula A and pharmaceutically acceptable salts thereof and crystalline Forms I and II of Compound of Formula A! Also, methods for the preparation of such compounds, pharmaceutical compositions comprising such compounds, and methods for their uses.
摘要:
Automated malware signature generation is disclosed. Automated malware signature generation includes monitoring incoming unknown files for the presence of malware and analyzing the incoming unknown files based on both a plurality of classifiers of file behavior and a plurality of classifiers of file content. An incoming file is classified as having a particular malware classification based on the analyzing of incoming unknown files and a malware signature is generated for the incoming unknown file based on the particular malware classification. Access is provided to the malware signature.